Amarin Corporation PLC at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good morning. We'll continue with the next session. I'm Paul Choi, SMID-Cap biotechnology analyst here at Goldman Sachs. It's my pleasure to introduce the management team from Amarin. With us today, we have John Thero and Karim Mikhail.
What we'll do is continue with the standard format. We'll let -- have John kick it off with some introductory remarks, and then we'll get into the Q&A. If clients along the way have questions, please feel free to e-mail them through the research portal here or to e-mail them to me directly, and time permitting, I will ask the management team the questions.
And with that, I'll turn it over to John.
Thanks, Paul, and thanks, everybody, for joining us here today. First, let me just state, I -- during this presentation, both Karim and I will be making forward-looking statements. There are risks involved with any such forward-looking statements, and investors should review our SEC filings before investing.
This is an
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
